Obsidian Therapeutics (OBX) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.19

Estimate

-$1.63

Surprise

+27.2%

Score at report (before → after)

4.8 → 4.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Obsidian Therapeutics (OBX) reported a narrower loss than forecast — adjusted EPS of -$1.19 against the -$1.63 estimate (a 27.2% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Data Issue (4.8/10) to Sell at 4.4/10 after the report — the engine's score fell despite the beat.

• Obsidian Therapeutics Files Prospectus Related To Resale Of Up To 29,164,045 Shares Of Common Stock By Selling Stockhold — benzinga, 2026-08-28

TrendMatrix currently rates OBX Sell at 6.0/10.

1 of the last 1 quarters beat the estimate; this quarter's +27.2% surprise compares with a +27.2% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$14.59

Price target

$33.15

Stop

$13.57

Upside to target

+127.2%

Reward-to-risk

8.5:1

Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$901.3M

P/E (fwd)

-6.8

52-week range

$11.52–$49.97

Off 52-week high

70.8%

RSI (14)

71

Volume vs avg

1.29×

Score today

6.0/10